SE9802549D0 - Quinoline derivatives - Google Patents
Quinoline derivativesInfo
- Publication number
- SE9802549D0 SE9802549D0 SE9802549A SE9802549A SE9802549D0 SE 9802549 D0 SE9802549 D0 SE 9802549D0 SE 9802549 A SE9802549 A SE 9802549A SE 9802549 A SE9802549 A SE 9802549A SE 9802549 D0 SE9802549 D0 SE 9802549D0
- Authority
- SE
- Sweden
- Prior art keywords
- fluoro
- chloro
- propyl
- proviso
- hydrogen
- Prior art date
Links
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000001153 fluoro group Chemical group F* 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 125000001246 bromo group Chemical group Br* 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- -1 methoxy, ethoxy Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000005784 autoimmunity Effects 0.000 abstract 1
- 150000001767 cationic compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 150000002892 organic cations Chemical class 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (34)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9802549A SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Quinoline derivatives |
| DE69911415T DE69911415T2 (de) | 1998-07-15 | 1999-07-14 | Chinolinderivate |
| IL14034699A IL140346A0 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
| PCT/SE1999/001270 WO2000003991A1 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
| TR2001/00087T TR200100087T2 (tr) | 1998-07-15 | 1999-07-14 | Kinolin türevleri |
| IDW20010331A ID27423A (id) | 1998-07-15 | 1999-07-14 | Turunan kuinolin |
| RU2001104342/04A RU2213733C2 (ru) | 1998-07-15 | 1999-07-14 | Производные хинолина, способ их получения (варианты), фармацевтическая композиция и способ лечения с их использованием |
| PT99933452T PT1095021E (pt) | 1998-07-15 | 1999-07-14 | Derivados de quinolina |
| BRPI9912109-3A BR9912109B1 (pt) | 1998-07-15 | 1999-07-14 | compostos derivados de quinolina, composições farmacêuticas, processo para a manufatura de um composto, e, uso de um composto. |
| AU49504/99A AU751103B2 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
| ES99933452T ES2205854T3 (es) | 1998-07-15 | 1999-07-14 | Derivados de quinolina. |
| MEP-574/08A MEP57408A (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
| KR10-2000-7014618A KR100516382B1 (ko) | 1998-07-15 | 1999-07-14 | 퀴놀린 유도체 |
| OA00100011A OA11906A (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives. |
| EP99933452A EP1095021B1 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
| AT99933452T ATE250036T1 (de) | 1998-07-15 | 1999-07-14 | Chinolinderivate |
| YUP-15/01A RS50128B (sr) | 1998-07-15 | 1999-07-14 | Derivati hinolina |
| APAP/P/2001/002041A AP1366A (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives. |
| HK01104765.4A HK1035715B (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
| JP2000560098A JP4045070B2 (ja) | 1998-07-15 | 1999-07-14 | キノリン誘導体 |
| UA2000127299A UA64791C2 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives, a method for the preparation thereof, a pharmaceutical composition and a method for treatment of diseases resulting from pathological inflammation or autoimmunity |
| EEP200100010A EE04673B1 (et) | 1998-07-15 | 1999-07-14 | Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid |
| CZ20010094A CZ300229B6 (cs) | 1998-07-15 | 1999-07-14 | Deriváty chinolinu |
| HR20010039A HRP20010039B1 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
| NZ508923A NZ508923A (en) | 1998-07-15 | 1999-07-14 | N-phenyl-1-Methyl-2-oxo-quinoline-3-carboxamide derivatives, pharmaceuticals thereof and their use in therapy |
| CA002336968A CA2336968C (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
| HU0103224A HU229427B1 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives, process for producing them and pharmaceutical compositions containing them |
| PL345388A PL199783B1 (pl) | 1998-07-15 | 1999-07-14 | Związki pochodne chinolino-3-karboksyamidu, zawierające je kompozycje farmaceutyczne, sposób ich wytwarzania i ich zastosowanie |
| CNB998085987A CN1157378C (zh) | 1998-07-15 | 1999-07-14 | 喹啉衍生物 |
| DK99933452T DK1095021T3 (da) | 1998-07-15 | 1999-07-14 | Quinolinderivater |
| IL140346A IL140346A (en) | 1998-07-15 | 2000-12-14 | Quinoline derivatives, pharmaceutical preparations containing them and a process for their preparation |
| IS5775A IS2208B (is) | 1998-07-15 | 2000-12-18 | Quinoline afleiður |
| ZA200007593A ZA200007593B (en) | 1998-07-15 | 2000-12-18 | Quinoline Derivatives. |
| NO20010211A NO317601B1 (no) | 1998-07-15 | 2001-01-12 | Kinolinderivater |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9802549A SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Quinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE9802549D0 true SE9802549D0 (sv) | 1998-07-15 |
Family
ID=20412093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE9802549A SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Quinoline derivatives |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP1095021B1 (cs) |
| JP (1) | JP4045070B2 (cs) |
| KR (1) | KR100516382B1 (cs) |
| CN (1) | CN1157378C (cs) |
| AP (1) | AP1366A (cs) |
| AT (1) | ATE250036T1 (cs) |
| AU (1) | AU751103B2 (cs) |
| BR (1) | BR9912109B1 (cs) |
| CA (1) | CA2336968C (cs) |
| CZ (1) | CZ300229B6 (cs) |
| DE (1) | DE69911415T2 (cs) |
| DK (1) | DK1095021T3 (cs) |
| EE (1) | EE04673B1 (cs) |
| ES (1) | ES2205854T3 (cs) |
| HR (1) | HRP20010039B1 (cs) |
| HU (1) | HU229427B1 (cs) |
| ID (1) | ID27423A (cs) |
| IL (2) | IL140346A0 (cs) |
| IS (1) | IS2208B (cs) |
| ME (1) | MEP57408A (cs) |
| NO (1) | NO317601B1 (cs) |
| NZ (1) | NZ508923A (cs) |
| OA (1) | OA11906A (cs) |
| PL (1) | PL199783B1 (cs) |
| PT (1) | PT1095021E (cs) |
| RS (1) | RS50128B (cs) |
| RU (1) | RU2213733C2 (cs) |
| SE (1) | SE9802549D0 (cs) |
| TR (1) | TR200100087T2 (cs) |
| UA (1) | UA64791C2 (cs) |
| WO (1) | WO2000003991A1 (cs) |
| ZA (1) | ZA200007593B (cs) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL199781B1 (pl) * | 1999-10-25 | 2008-10-31 | Active Biotech Ab | Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania |
| SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| EP1512396A4 (en) * | 2002-06-05 | 2008-12-31 | Inst Med Molecular Design Inc | HEMMER AGAINST ACTIVATION OF AP-1 AND NFAT |
| CN1658855B (zh) | 2002-06-06 | 2010-04-28 | 株式会社医药分子设计研究所 | O-取代羟基芳基衍生物 |
| EA011707B1 (ru) * | 2002-06-11 | 2009-04-28 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | Лекарственное средство для лечения нейродегенеративных заболеваний |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| SE0401578D0 (sv) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
| EP2687512A1 (en) | 2005-10-19 | 2014-01-22 | Teva Pharmaceutical Industries Ltd. | Crystals of Laquinimod Sodium, and Process for the Manufacture Thereof |
| ATE532515T1 (de) | 2006-06-12 | 2011-11-15 | Teva Pharma | Stabile laquinimod-zubereitungen |
| WO2008113006A1 (en) * | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
| PL2234485T3 (pl) | 2007-12-20 | 2014-06-30 | Teva Pharma | Stabilne preparaty lakwinimodu |
| ES2633658T3 (es) | 2008-09-03 | 2017-09-22 | Teva Pharmaceutical Industries Ltd. | Moduladores 2-oxo-1,2-dihidro-quinolina de la función inmunitaria |
| DE102010048788A1 (de) | 2009-02-13 | 2011-05-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
| DE102009008851A1 (de) | 2009-02-13 | 2010-08-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
| MX2012001333A (es) | 2009-07-30 | 2012-06-01 | Teva Pharma | Tratamiento de la enfermedad de crohn con la laquinimod. |
| EP2467372B1 (en) | 2009-08-10 | 2016-05-18 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| DE102010026879A1 (de) | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermales System mit Immunmodulator |
| KR20150135552A (ko) | 2010-03-03 | 2015-12-02 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
| EP2542079B1 (en) | 2010-03-03 | 2014-05-21 | Teva Pharmaceutical Industries Ltd. | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
| CA2804986A1 (en) | 2010-07-09 | 2012-01-12 | Teva Pharmaceutical Industries Ltd. | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| ES2537615T3 (es) * | 2010-08-27 | 2015-06-10 | Grünenthal GmbH | 2-Oxo- y 2-tioxo-dihidroquinolina-3-carboxamidas sustituidas como moduladores de KCNQ2/3 |
| US8962598B2 (en) * | 2010-10-14 | 2015-02-24 | Immunahr Ab | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AHR activators |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| CA2851525A1 (en) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| SG11201404214QA (en) | 2012-02-03 | 2014-08-28 | Teva Pharma | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
| BR112014020372A8 (pt) | 2012-02-16 | 2018-01-23 | Teva Pharma | n-etil-n-fenil-1,2-di-hidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, preparação e utilização do mesmo |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| JP2015535287A (ja) | 2012-11-07 | 2015-12-10 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドのアミン塩 |
| JP5868839B2 (ja) | 2012-12-27 | 2016-02-24 | 三菱重工業株式会社 | チャー払出管 |
| CN105051013A (zh) | 2013-03-14 | 2015-11-11 | 泰华制药工业有限公司 | 拉喹莫德钠晶体及其改进的制造方法 |
| HK1231413A1 (zh) | 2014-04-29 | 2017-12-22 | Teva Pharmaceutical Industries Ltd. | 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德 |
| CN105367492B (zh) * | 2014-08-28 | 2018-07-03 | 杭州普晒医药科技有限公司 | 他喹莫德的晶型及其制备方法、其药物组合物和用途 |
| EA030948B1 (ru) | 2014-09-23 | 2018-10-31 | Эктив Байотек Аб | Хинолинкарбоксамиды для применения в лечении множественной миеломы |
| MX379401B (es) | 2014-11-19 | 2025-03-11 | Active Biotech Ab | Carboxamidas de quinolina para usarse en el tratamiento de leucemia. |
| EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
| WO2018105943A1 (ko) * | 2016-12-07 | 2018-06-14 | 순천향대학교 산학협력단 | 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물 |
| ES3032708T3 (en) | 2020-03-03 | 2025-07-23 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
| JP7747732B2 (ja) | 2020-07-23 | 2025-10-01 | イラスマス・ユニバーシティ・メディカル・センター・ロッテルダム | 骨髄増殖性腫瘍における新規治療用標的としてのｓ１００タンパク質 |
| MX2023008016A (es) | 2021-01-18 | 2023-07-13 | Active Biotech Ab | Tasquinimod o una sal farmaceutica aceptable para su uso en el tratamiento del sindrome mielodisplasico. |
| CA3218977A1 (en) | 2021-05-25 | 2022-12-01 | Hans Wannman | A plurality of tasquinimod particles and use thereof |
| WO2023275248A1 (en) | 2021-07-02 | 2023-01-05 | Active Biotech Ab | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
| AR126963A1 (es) * | 2021-09-13 | 2023-12-06 | Lilly Co Eli | Agonistas de ahr |
| TWI838849B (zh) * | 2021-09-13 | 2024-04-11 | 美商美國禮來大藥廠 | Ahr促效劑 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
| DE4120646A1 (de) * | 1991-06-22 | 1992-12-24 | Bayer Ag | 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate |
| SE469368B (sv) * | 1991-10-09 | 1993-06-28 | Kabi Pharmacia Ab | Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms) |
| SE9201076L (sv) * | 1992-04-06 | 1993-10-07 | Shimon Slavin | Användningen av gamla läkemedel för behandling av diabetes |
| JPH07224040A (ja) * | 1994-02-07 | 1995-08-22 | Fujisawa Pharmaceut Co Ltd | キノリン誘導体 |
| GB9404378D0 (en) * | 1994-03-07 | 1994-04-20 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
| SE9400809D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of quinoline-3-carboxamide compounds |
| SE9400810D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of Quinoline-3-carboxamide compounds |
| GB2290786A (en) * | 1994-06-30 | 1996-01-10 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
-
1998
- 1998-07-15 SE SE9802549A patent/SE9802549D0/xx unknown
-
1999
- 1999-07-14 TR TR2001/00087T patent/TR200100087T2/xx unknown
- 1999-07-14 AU AU49504/99A patent/AU751103B2/en not_active Ceased
- 1999-07-14 PT PT99933452T patent/PT1095021E/pt unknown
- 1999-07-14 PL PL345388A patent/PL199783B1/pl unknown
- 1999-07-14 CN CNB998085987A patent/CN1157378C/zh not_active Expired - Fee Related
- 1999-07-14 CA CA002336968A patent/CA2336968C/en not_active Expired - Fee Related
- 1999-07-14 KR KR10-2000-7014618A patent/KR100516382B1/ko not_active Expired - Fee Related
- 1999-07-14 DE DE69911415T patent/DE69911415T2/de not_active Expired - Lifetime
- 1999-07-14 OA OA00100011A patent/OA11906A/en unknown
- 1999-07-14 AT AT99933452T patent/ATE250036T1/de active
- 1999-07-14 NZ NZ508923A patent/NZ508923A/xx not_active IP Right Cessation
- 1999-07-14 HR HR20010039A patent/HRP20010039B1/xx not_active IP Right Cessation
- 1999-07-14 RS YUP-15/01A patent/RS50128B/sr unknown
- 1999-07-14 ES ES99933452T patent/ES2205854T3/es not_active Expired - Lifetime
- 1999-07-14 UA UA2000127299A patent/UA64791C2/uk unknown
- 1999-07-14 HU HU0103224A patent/HU229427B1/hu not_active IP Right Cessation
- 1999-07-14 ID IDW20010331A patent/ID27423A/id unknown
- 1999-07-14 EE EEP200100010A patent/EE04673B1/xx unknown
- 1999-07-14 IL IL14034699A patent/IL140346A0/xx active IP Right Grant
- 1999-07-14 BR BRPI9912109-3A patent/BR9912109B1/pt not_active IP Right Cessation
- 1999-07-14 WO PCT/SE1999/001270 patent/WO2000003991A1/en not_active Application Discontinuation
- 1999-07-14 CZ CZ20010094A patent/CZ300229B6/cs not_active IP Right Cessation
- 1999-07-14 AP APAP/P/2001/002041A patent/AP1366A/en active
- 1999-07-14 DK DK99933452T patent/DK1095021T3/da active
- 1999-07-14 JP JP2000560098A patent/JP4045070B2/ja not_active Expired - Fee Related
- 1999-07-14 ME MEP-574/08A patent/MEP57408A/xx unknown
- 1999-07-14 RU RU2001104342/04A patent/RU2213733C2/ru not_active IP Right Cessation
- 1999-07-14 EP EP99933452A patent/EP1095021B1/en not_active Expired - Lifetime
-
2000
- 2000-12-14 IL IL140346A patent/IL140346A/en not_active IP Right Cessation
- 2000-12-18 ZA ZA200007593A patent/ZA200007593B/xx unknown
- 2000-12-18 IS IS5775A patent/IS2208B/is unknown
-
2001
- 2001-01-12 NO NO20010211A patent/NO317601B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE9802549D0 (sv) | Quinoline derivatives | |
| SE9801474D0 (sv) | Quinoline Derivatives | |
| AP1425A (en) | Quinoline derivatives. | |
| TR200000837A2 (tr) | Anti-kanser bileşimleri hazırlamak için işlem ve ara maddeler. | |
| ATE37179T1 (de) | Dihydropyridazinone. | |
| ATE247654T1 (de) | Neue heterozyklische verbindungen | |
| ATE139233T1 (de) | Annelierte thiophen-derivate, ihre herstellung und verwendung | |
| NZ336302A (en) | Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia | |
| EA200300716A1 (ru) | Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6 | |
| BR0213731A (pt) | Compostos de silìcio | |
| DE69312567D1 (de) | 2-Formylpyridin-Thiosemicarbazonderivate, ihre Herstellung und ihre Verwendung als Antitumor Mittel | |
| DE60202682D1 (de) | Chinoline derivate und ihre anwendung als antitumor agentien | |
| ATE216233T1 (de) | Indolditerpen alkaloide | |
| EA200101050A1 (ru) | Замещенные бензолактамные соединения | |
| DK1082116T3 (da) | Anvendelse af 4-piperidinmethanolderivater til behandling af neurologiske sygdomme | |
| MXPA04000615A (es) | Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor. | |
| SE0401578D0 (sv) | Novel compounds | |
| IE832466L (en) | Indoles and intermediates. | |
| IT1205640B (it) | Nuovi composti ad attivita' antiinfiammatoria,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono | |
| ATE56442T1 (de) | 2,6-piperazin-dion-derivate, ihre verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen. | |
| SE0400440D0 (sv) | Novel Cinnamic Amides | |
| DK0660840T3 (da) | Phosphono-substituerede tetrazolderivater. | |
| MX9601953A (es) | Nuevo compesto derivados de 5h-tiazolo [3,2-a] pirimidin-5-ona. | |
| MX9705144A (es) | Uso de un compuesto de carboestirilo para preparar un inhibidor de la produccion o secrecion del factor de necrosis tumoral alfa. |